Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Clinical
  3. /Readouts

Clinical

Readouts(70)

Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.

70 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
7.0

CLINICAL

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

Roche·Herceptin·June 18, 2026
7.0

CLINICAL

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

Novartis·Dabrafenib·June 18, 2026
7.0

CLINICAL

Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques

The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.

heart failure·Cardiology·June 18, 2026
7.0

CLINICAL

Study on ACS Geriatric Surgery Program's Impact on Older Cancer Patients

The study evaluates the implementation of the ACS GSV Program at James Cancer Hospital to enhance surgical outcomes for older adults.

cancer·Oncology·June 18, 2026
7.0

CLINICAL

Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.

Novartis·children undergoing cancer treatment·June 18, 2026
7.0

CLINICAL

ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer

The ROBIN trial will investigate the molecular effects of standard short course radiotherapy on rectal cancer and its impact on the immune system.

National Cancer Institute·Oncology·June 17, 2026
7.0

CLINICAL

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

Roche·Herceptin·June 17, 2026
8.0

CLINICAL

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.

Heart Failure·Cardiology·June 17, 2026
7.0

CLINICAL

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.

AstraZeneca·Durvalumab·June 17, 2026
7.0

CLINICAL

Nemtabrutinib Study vs Ibrutinib/Acalabrutinib in 1L CLL/SLL Initiated

A study is underway to evaluate nemtabrutinib against ibrutinib or acalabrutinib in treatment-naive CLL/SLL patients.

Merck·Nemtabrutinib·June 17, 2026
7.0

CLINICAL

Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority

A randomized trial is assessing whether S-ICD implantation without defibrillation testing is non-inferior to the standard method.

Medtronic·Cardiology·June 17, 2026
7.0

CLINICAL

R-MVST Cells Show Promise for Treating Refractory Viral Infections

A clinical trial is assessing the safety and feasibility of R-MVST cells for patients with refractory viral infections caused by EBV, CMV, ADV, or BK virus.

Novartis·Infectious Disease·June 17, 2026
8.0

CLINICAL

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

Roche·trastuzumab·June 17, 2026
8.0

CLINICAL

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

The OTAC trial is assessing the safety and efficacy of hIVIG versus placebo in outpatients with COVID-19.

GSK·COVID-19·June 17, 2026
7.0

CLINICAL

Study on PSB Pacing to Prevent Atrial Fibrillation in Sinus Node Dysfunction Patients

A clinical trial is evaluating the effectiveness of posterosuperior bundle pacing in reducing atrial fibrillation incidence in patients with sinus node dysfunction.

Medtronic·Atrial Fibrillation·June 17, 2026
7.0

COMPETITIVE

Boomerang Medical initiates pivotal trial for device in ulcerative colitis

Boomerang Medical is conducting a pivotal trial to evaluate a device aimed at reducing bowel urgency in ulcerative colitis patients.

ulcerative colitis·Gastroenterology·June 17, 2026
7.0

CLINICAL

DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated

A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.

DB Pharma·BNT323·June 17, 2026
7.0

CLINICAL

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

Pfizer·Prostate Cancer·June 17, 2026
7.0

CLINICAL

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

Roche·Herceptin·June 17, 2026
7.0

CLINICAL

KSHB002 Trial Shows Equivalence to ORENCIA in PK, Safety, and Immunogenicity for RA

The trial aims to establish the pharmacokinetic equivalence, safety, and immunogenicity of KSHB002 compared to ORENCIA in healthy subjects.

KSHB Biopharma·KSHB002·June 17, 2026
8.0

CLINICAL

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Polyploid giant cancer cells (PGCCs) contribute to therapy resistance and poor prognosis in ovarian cancer.

Bristol-Myers Squibb·Olaparib·June 17, 2026
8.0

CLINICAL

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

Bristol-Myers Squibb·Keytruda·June 17, 2026
8.0

CLINICAL

Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment

Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.

Bayer·Flutamide·June 17, 2026
7.0

CLINICAL

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

Pfizer·Keytruda·June 17, 2026
8.0

CLINICAL

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

Amgen·Keytruda·June 17, 2026

Showing 1–25 of 70 records

Page 1 of 3